A Single Blind, Fixed Sequence, Single-dose Study to Evaluate the Serious Risk of QTc Prolongation With Quizartinib in Healthy Subjects Under Rapid Acceleration of Heart Rate
Latest Information Update: 20 Jan 2025
Price :
$35 *
At a glance
- Drugs Quizartinib (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- Sponsors Daiichi Sankyo Company
- 20 Jan 2025 New trial record